Penn Medicine and Boston-area biopharm firm to pursue potential solid tumor CAR T-cell therapy


A University of Pennsylvania center led by a cell therapy pioneer has formed a research collaboration with Needham's Candel Therapeutics aimed at advancing a way to use CAR T-cell therapy to combat solid tumors.

Previous Foundation invests in the health of Arizona’s communities
Next A biopharma firm with a unique public-private model opens in Watertown